Pfizer strives to become the leading biotherapeutics company by building on internal expertise and fostering strategic partnerships to access the best technologies with patent protection and technical capabilities that provide a competitive advantage.

WRD is interested in establishing alliances to develop and access:

  • Transformational technologies to design, construct, and optimize biotherapeutics
    • nformed protein design optimizes molecular properties resulting in superior efficacy, pharmacokinetics, pharmacodynamics, safety, manufacturability and differentions
  • Antibody drug conjugate technologies
    • Novel ADC platforms, novel payloads, linkers, conjugation sites
  • Bioconjugation technologies
    • Novel approaches that enhance antibody function or improve site-specific bioconjugation
  • Combinatorial biologics such as bi-specific and multi-functional platforms with promising biophysical and manufacturing properties
  • Structure-based and computational design of therapeutics
    • Novel technologies to rationally design antibody, protein and peptide therapeutics that display superior pharmaceutical properties (including selectivity, half-life extension, stability, formulatability)
  • Technologies that enhance multi-transmembrane protein target expression/presentation for antibody generation and screening
  • Technologies and patient sample access for antibody discovery from human antibody responses
  • Targeted delivery technologies that address/ overcome cell membrane penetration, cross blood brain barrier
  • Technologies that can significantly enhance general protein expression, purification, stability for discovery
  • Integrated service providers to support early discovery activities for development of therapeutics
  • Broadly applicable platforms to enhance speed/ quality of antibody generation
  • Novel biologics, combination therapies, and "biobetters" that fit Pfizer strategies

Not actively seeking partnering opportunities in:

  • PEGylation for bioconjugation
  • Protein scaffold platforms with challenging stability attributes and/or difficult manufacturability